Amended April 7, 2015 Sioux Pharm, Inc. And Sioux Biochemical, Inc. v. Summit Nutritionals International, Inc.

CourtSupreme Court of Iowa
DecidedJanuary 30, 2015
Docket13–1756
StatusPublished

This text of Amended April 7, 2015 Sioux Pharm, Inc. And Sioux Biochemical, Inc. v. Summit Nutritionals International, Inc. (Amended April 7, 2015 Sioux Pharm, Inc. And Sioux Biochemical, Inc. v. Summit Nutritionals International, Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of Iowa primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Amended April 7, 2015 Sioux Pharm, Inc. And Sioux Biochemical, Inc. v. Summit Nutritionals International, Inc., (iowa 2015).

Opinion

IN THE SUPREME COURT OF IOWA No. 13–1756

Filed January 30, 2015 Amended April 7, 2015

SIOUX PHARM, INC. and SIOUX BIOCHEMICAL, INC.,

Appellees,

vs.

SUMMIT NUTRITIONALS INTERNATIONAL, INC.,

Appellant.

Appeal from the Iowa District Court for Sioux County, Duane E.

Hoffmeyer, Judge.

Defendant appeals order denying motion to dismiss for lack of

personal jurisdiction. AFFIRMED.

Daniel J. Fischer, Brian J. Koenig, and J. Daniel Weidner of Koley

Jessen, P.C., L.L.O., Omaha, Nebraska, for appellant.

Anthony L. Osborn and Jeana L. Goosmann of Goosmann Law

Firm, PLC, Sioux City, for appellees. 2

WATERMAN, Justice.

This appeal provides our first opportunity to address when

statements on a website support personal jurisdiction and the impact of

recent United States Supreme Court precedent on the showing required

for general jurisdiction. Specifically, we must decide whether a

nonresident corporation’s inaccurate statement on its passive website—

that it had a manufacturing facility in Sioux Center, Iowa—subjected it

to personal jurisdiction in Iowa in a lawsuit by an Iowa plaintiff alleging

unfair competition. The district court denied the nonresident

defendant’s motion to dismiss, ruling that general jurisdiction was

established simply because its website held this defendant out as having

an Iowa manufacturing facility. The Sioux Center facility actually is

owned and operated by a separate Iowa defendant that supplies the

product to the nonresident defendant. We allowed the nonresident

defendant’s interlocutory appeal of the jurisdictional ruling.

For the reasons explained below, we hold the district court erred

by exercising general jurisdiction over Summit based solely on the

inaccurate statement on its passive website. Recent precedent requires

proof the nonresident defendant is “essentially at home in the forum

State” to establish general jurisdiction. See Goodyear Dunlop Tires

Operations, S.A. v. Brown, 564 U.S. ___, ___, 131 S. Ct. 2846, 2851, 180

L. Ed. 2d 796, 803 (2011). That proof is lacking here. Nevertheless, we

hold the totality of the nonresident’s contacts with Iowa, including its

website statement, Iowa supply contract, and its sale of the product to

the plaintiff in Iowa were sufficient to subject it to specific jurisdiction

here on claims related to those contacts. We therefore affirm the order

denying its motion to dismiss on this alternative ground. 3

I. Background Facts and Proceedings.

Plaintiff Sioux Pharm, Inc. 1 is an Iowa corporation that

manufactures chondroitin sulfate, a supplement for joint health usually

mixed with glucosamine to help lessen the effects of osteoarthritis. Eagle

Laboratories, Inc. (Eagle Labs) is an Iowa corporation and a competitor of

Sioux Pharm. Eagle Labs sells and ships chondroitin sulfate monthly to

Summit Nutritionals International, Inc. (Summit), a New Jersey

corporation with its principal place of business in Branchburg,

New Jersey. Summit packages and resells the chondroitin sulfate.

At the time this lawsuit was filed, Summit’s website erroneously

claimed that Summit had a manufacturing facility in Sioux Center, Iowa.

The website read, “Manufacturing Facility, Summit Nutritionals

International, Inc.,” and for contact information listed a Sioux Center,

Iowa physical address and an email address. In fact, the Sioux Center

facility at that physical address has always been owned and operated by

Eagle Labs. Summit admits it listed the facility on its website to inform

its customers as to the Iowa source of Summit’s chondroitin sulfate,

which is derived from bovine organs.

Summit actually has no Iowa office, agent, or employees. It has

never been registered to do business in Iowa, and neither owns nor

leases any real or personal property in Iowa. Summit has no Iowa bank

accounts and has never been a party in litigation in Iowa before this

case. Summit has never specifically directed advertising at Iowa markets

or sold its product to anyone in Iowa except for a sample purchased by

Sioux Pharm to test for purposes of this lawsuit. Summit purchases its

1Plaintiff Sioux Biochemical, Inc. is a sister corporation to Sioux Pharm, Inc. We

will refer to the entities together as Sioux Pharm. 4

chondroitin sulfate from Eagle Labs under an annual contract to supply

Summit’s requirements through monthly shipments. Summit’s president

traveled to Iowa once to inspect Eagle Labs’ facility, but he flew in and

out of an airport in South Dakota and only spent a few hours in Iowa.

No other employee of Summit has ever visited Iowa on its behalf.

Sioux Pharm filed suit against Eagle Labs and its principals, Dana

Summers, Robert Den Hoed, and John Ymker on March 8, 2012. The

initial pleading alleged claims for the misappropriation of trade secrets,

which are the subject of a separate, pending interlocutory appeal. See

Sioux Pharm, Inc. v. Eagle Labs, Inc., No. 13–1756 (Iowa filed

September 27, 2013). Sioux Pharm’s second amended petition, the

operative pleading here, was filed April 23, 2013. That pleading added

claims of unfair competition, intentional interference with contractual

relationships, and civil conspiracy and named Summit and Federal

Laboratories Corporation (Federal Labs), a New York corporation, as

additional defendants. Sioux Pharm specifically alleged Summit, Federal

Labs, and Eagle Labs conspired to distribute adulterated and diluted

chondroitin sulfate while misrepresenting its purity, in violation of

§ 1125(a) of the Lanham Act, 15 U.S.C. §§ 1051–1141n (2012). On

June 7, the district court, pursuant to Iowa Rule of Civil Procedure

1.914, granted Summit’s motion to bifurcate the trade-secret claims from

the unfair-competition claims.

Both Summit and Federal Labs moved to dismiss for lack of

personal jurisdiction. Both nonresident defendants filed affidavits

attesting to their lack of contacts with Iowa. Sioux Pharm filed

resistances and argued as to Summit that its website statement along

with its contract with Eagle Labs and site visit there were sufficient to

subject it to general jurisdiction or, alternatively, specific jurisdiction. 5

The district court granted Federal Labs’ motion, determining that

Sioux Pharm “failed to present a prima facie case” sufficient to justify

personal jurisdiction on a conspiracy theory and that Federal Labs lacks

contacts with Iowa sufficient for general jurisdiction. However, the

district court denied Summit’s motion, stating:

Although Summit presents this Court with many facts to establish that it has no systematic or continuous ties to the State of Iowa, this Court does not find those facts to be persuasive. Although Summit may not have an office or real property in Iowa, it holds itself out as having both. Summit’s website clearly states that it has a manufacturing facility in Sioux Center, Iowa. . . .

Free access — add to your briefcase to read the full text and ask questions with AI

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
McGee v. International Life Insurance
355 U.S. 220 (Supreme Court, 1957)
World-Wide Volkswagen Corp. v. Woodson
444 U.S. 286 (Supreme Court, 1980)
Calder v. Jones
465 U.S. 783 (Supreme Court, 1984)
Helicopteros Nacionales De Colombia, S. A. v. Hall
466 U.S. 408 (Supreme Court, 1984)
Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Krepps v. Reiner
377 F. App'x 65 (Second Circuit, 2010)
Johnson v. Arden
614 F.3d 785 (Eighth Circuit, 2010)
Chloé v. Queen Bee of Beverly Hills, LLC
616 F.3d 158 (Second Circuit, 2010)
Goodyear Dunlop Tires Operations, S. A. v. Brown
131 S. Ct. 2846 (Supreme Court, 2011)
CollegeSource, Inc. v. AcademyOne, Inc.
653 F.3d 1066 (Ninth Circuit, 2011)
Dakota Industries, Inc. v. Dakota Sportswear, Inc.
946 F.2d 1384 (Eighth Circuit, 1991)
Donald Bruce Sondergard v. Miles, Inc.
985 F.2d 1389 (Eighth Circuit, 1993)
Bell Paper Box, Inc. v. U.S. Kids, Inc.
22 F.3d 816 (Eighth Circuit, 1994)
Capital Promotions, L.L.C. v. Don King Productions, Inc.
756 N.W.2d 828 (Supreme Court of Iowa, 2008)
Bankers Trust Co. v. Fidata Trust Co. New York
452 N.W.2d 411 (Supreme Court of Iowa, 1990)
Christy v. Miulli
692 N.W.2d 694 (Supreme Court of Iowa, 2005)
Central Life Insurance Co. v. Aetna Casualty & Surety Co.
466 N.W.2d 257 (Supreme Court of Iowa, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
Amended April 7, 2015 Sioux Pharm, Inc. And Sioux Biochemical, Inc. v. Summit Nutritionals International, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/amended-april-7-2015-sioux-pharm-inc-and-sioux-biochemical-inc-v-iowa-2015.